Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,756 across all filing types
Latest filing 2025-06-29 M&A Activity
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Agreements
M&A Activity Classification · 95% confidence The document is a detailed announcement from Torrent Pharmaceuticals Limited regarding the approval by its Board of Directors of a significant acquisition and merger transaction involving J.B. Chemicals & Pharmaceuticals Limited. It includes specifics about share acquisition, open offer, merger scheme, regulatory approvals required, and financial details of the target company. The content focuses on a merger and acquisition transaction, including execution of a merger implementation agreement and scheme of amalgamation under the Companies Act. The document is not a full annual or interim report, nor is it a simple announcement of a report publication. It is not a call transcript, earnings release, or governance information. The detailed nature of the transaction and regulatory references align with the category for M&A Activity (TAR). Therefore, the document is best classified as M&A Activity (TAR).
2025-06-29 English
Announcement under regulation 30 (LODR) - Acquisition
M&A Activity Classification · 95% confidence The document is a detailed announcement from Torrent Pharmaceuticals Limited regarding the approval by its Board of Directors of a significant acquisition and merger transaction involving J.B. Chemicals & Pharmaceuticals Limited. It includes specifics about share acquisition, open offer, merger scheme, regulatory approvals, and financial details of the target company. The content focuses on a merger and acquisition activity, including execution of a merger implementation agreement and regulatory compliance under SEBI regulations. There is no indication that this is a full annual report, earnings release, or other financial report. The document is not a simple announcement of a report publication but a substantive disclosure of a major corporate transaction. Therefore, the document fits best under the category of M&A Activity (TAR).
2025-06-29 English
Outcome of Board Meeting
M&A Activity Classification · 95% confidence The document is a detailed announcement from Torrent Pharmaceuticals Limited regarding the approval by its Board of Directors of a significant acquisition and merger transaction involving J.B. Chemicals & Pharmaceuticals Limited. It includes specifics about share acquisition, open offer, merger scheme, regulatory approvals required, and financial details of the target company. The document references compliance with SEBI Listing Regulations and Takeover Regulations, and includes annexures with detailed transaction information. This is a regulatory announcement about a major M&A transaction, not a full annual or interim report, earnings release, or other financial report. It is not a proxy, voting result, or remuneration report. The content fits the category of M&A Activity filings, which cover announcements and documents related to merger proposals or takeover bids.
2025-06-29 English
Disclosure pursuant to Regulation 30 read with Schedule III and Regulation 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations')
M&A Activity Classification · 95% confidence The document is a detailed announcement from Torrent Pharmaceuticals Limited regarding the approval by its Board of Directors of a significant acquisition and merger transaction involving J.B. Chemicals & Pharmaceuticals Limited. It includes specifics about share acquisition, open offer, merger scheme, regulatory approvals required, and financial details of the target company. The document is a formal disclosure pursuant to SEBI Listing Regulations, describing a major corporate transaction (acquisition and merger). It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about a merger and acquisition activity. Therefore, the most appropriate classification is 'M&A Activity' (Code: TAR). The document length and detail support a high confidence score.
2025-06-29 English
Redemption of Commercial Paper Issued under ISIN INE685A14120
Capital/Financing Update Classification · 95% confidence The document is a short notification about the redemption of commercial papers by the company, referencing compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30. It is an update on a financing activity (repayment of debt instrument) rather than a full financial report or earnings release. The document length is only 1207 characters, indicating it is a brief announcement. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-06-27 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a short notification about the redemption of commercial papers by the company, referencing compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is an update on a financing activity (repayment of debt instrument) rather than a full financial report or earnings release. The document length is only 1207 characters, indicating it is a brief announcement. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-06-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.